Skip to content

Targeting PPP1R14B overcomes immunotherapy resistance in prostate cancer by restoring CD8+ T-cell infiltration via the Nrf2/CX3CL1 axis.

Sep 2026 · Journal of Pathology · 0 citations · 27 references
Medicine

TL;DR

PPP1R14B (PP1 regulatory inhibitor subunit 14B) was overexpressed in PCa and associated with poor prognosis, promoting PCa cell proliferation, suppressing apoptosis, and correlating with increased tumor purity but reduced CD8+ T-cell infiltration.

Abstract

Prostate cancer (PCa) is typically immunologically 'cold', which limits the effectiveness of immunotherapy, and this study sought to identify key genes driving this immunosuppressive phenotype and assess their therapeutic potential. We analyzed transcriptomic data from 487 TCGA-PRAD patients and three Gene Expression Omnibus datasets; weighted gene co-expression network analysis was used to identify cancer-related genes, TIMER to evaluate their influence on the tumor microenvironment, and findings were validated via flow cytometry on 32 clinical PCa specimens. Immunoblotting measured Nrf2, p-AKT, and p-GSK-3β levels, while ChIP-qPCR assessed Nrf2 and RNA polymerase II binding to the CX3CL1 promoter, and functional studies were conducted in allograft and xenograft mouse models using GapmeR antisense oligonucleotides combined with anti-PD-1 antibodies or PSMA-targeted CAR-T cells. We found PPP1R14B (PP1 regulatory inhibitor subunit 14B) was overexpressed in PCa and associated with poor prognosis, promoting PCa cell proliferation, suppressing apoptosis, and correlating with increased tumor purity but reduced CD8+ T-cell infiltration; mechanistically, CX3CL1 was regulated by Nrf2 and PPP1R14B elevated p-AKT/p-GSK-3β to stabilize Nrf2, which bound the CX3CL1 promoter, suppressed its expression, and impaired CD8+ T-cell chemotaxis. GapmeR-mediated PPP1R14B knockdown suppressed tumor growth and enhanced anti-PD-1/CAR-T efficacy in mice, indicating PPP1R14B is a promising target to overcome PCa immunotherapy resistance. © 2026 The Pathological Society of Great Britain and Ireland.

View source

Similar papers

Open access Oct 2026

Disruption of ACTG1 potentiates anti-TIM-3 immunotherapy by reprogramming the immunosuppressive microenvironment via the CSF3/CSF3R axis in pancreatic cancer

Background The limited immune infiltration observed in pancreatic ductal adenocarcinoma (PDAC) is a major factor contributing to immunotherapy resistance and the consistently poor prognosis. Hence, identifying novel therapeutic targets and developing effective combination strategies to overcome immunotherapy resistance...

Le Zhu, Yu Guo, Xin-Xin Ling et al. · 0 citations
Open access Aug 2026

ST6GAL1 promotes cancer stem-like cell-associated paclitaxel resistance through the EGFR-mTOR-SOX2/BMI1 axis in non-small cell lung cancer

ST6GAL1-mediated α2,6-sialylation of EGFR contributes to the maintenance of CSLC-associated paclitaxel resistance through mTOR-SOX2/BMI1 signaling, which identifies ST6GAL1-dependent EGFR sialylation as a potential therapeutic target in CSLC-associated chemoresistance.

Yu-Xi Yang, Bing-Hui Liang, W. Hong et al. · 1 citation
Open access Aug 2026

CDO1 as a prognostic biomarker and therapeutic target in gastric cancer: Mechanistic insights into the PI3K/AKT‐THBS1 axis and epigenetic reactivation by decitabine

Abstract Background As a pivotal metabolic enzyme, cysteine dioxygenase type 1 (CDO1) exerts tumour‐suppressive effects across diverse tumour types, and its expression is strongly correlated with clinical prognosis. However, the molecular mechanisms underlying CDO1‐mediated tumour suppression in gastric cancer (GC), it...

Fazhi Wang, Run-Kai Zhou, Jinfeng Cai et al. · 0 citations
Open access Oct 2026

SERPINB9 Promotes Colorectal Cancer Liver Metastasis and Immunotherapy Resistance: Association With MHC‐I Downregulation and CD8 + T Cell Dysfunction

Colorectal cancer liver metastasis (CRLM) is the leading cause of mortality in colorectal cancer (CRC) patients, for which effective treatments remain limited. The mechanisms by which tumor cells evade immune surveillance and escape cytotoxic killing remain poorly understood. SERPINB9 (SB9) has been implicated in...

Xin Liu, Wen-Chen Wang, Hong-Qian Wang et al. · 0 citations
2026

Modulation of CCL5 and CXCR4 as EMT signaling biomarkers by cold atmospheric plasma and Anti-PD-1 combination therapy in melanoma: Insights from integrated bioinformatics and in vitro and in vivo validation

Objective(s): Cold atmospheric plasma (CAP) has emerged as a promising non-thermal modality with anticancer effects. Combining CAP with immune checkpoint blockade (ICB) may enhance therapeutic efficacy, yet the molecular targets underlying this synergy remain incompletely understood. Materials and Methods: Epithelial--...

Zeinab Rostami, F. Akhoundi, Zahra Yazdani et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.